Synthesis and Biological Evaluation of Novel 1,2,3-Triazole derivatives as Anti-TB Agents

dc.contributor.advisor
dc.contributor.advisor
dc.contributor.author	Ali, Abdul A.
dc.contributor.author	Gogoi, Dhrubajyoti
dc.contributor.author	Buragohain, Alak K.
dc.contributor.author	Saikia, Prakash J.
dc.contributor.author	Gehlot, Praveen S
dc.contributor.author	Kumar, Arvind
dc.contributor.author	Trivedi, Priyanka
dc.contributor.author	Chaturvedi, Vinita
dc.contributor.author	Sarma, Diganta
dc.date.accessioned	2021-05-27T11:16:05Z
dc.date.available	2021-05-27T11:16:05Z
dc.date.issued	2016
dc.identifier.uri	http://dkr.cdri.res.in/xmlui/handle/1/1718
dc.description.abstract	A series of seventeen novel 1,2,3-Triazole derivatives were efficiently synthesized in excellent yields by the popular ‘click chemistry’ approach and evaluated for their in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Ra. Molecular docking of the target compounds into the active site of DprE1 (Decaprenylphosphoryl-β-D-ribose-2′-epimerase) enzyme revealed significant structural information on the plausible binding interactions	en_US
dc.language.iso	en	en_US
dc.publisher	CSIR-CDRI	en_US
dc.relation.ispartofseries	9516;
dc.subject	Tuberculosis, 1,2,3-Triazoles, antimycobacterial activity, molecular docking	en_US
dc.title	Synthesis and Biological Evaluation of Novel 1,2,3-Triazole derivatives as Anti-TB Agents	en_US
dc.type	Article	en_US